Newly developed compounds F2S4-m and F3S4-m are proposed as potential multitarget therapeutics for the AD as these molecules have shown to inhibit three important pharmacological targets in the AD, Aβ1–42 aggregation, and AChE and BACE1 enzyme activities in vitro. The gene discussed is BACE1; the disease is Alzheimer disease.